Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ramalingam

Showing results (161-170 of 502) with videos related to

Pageof 51
Sort By:
Current Oncology (Toronto, Ont.)|December 31, 2015
Analysis of liver-directed therapies in U.S. cancer patientsO B Alese, S Kim, Z Chen, et al.
Nature Reviews. Clinical Oncology|November 29, 2024
The changing treatment landscape of EGFR-mutant non-small-cell lung cancerFei Zhou, Haoyue Guo, Yang Xia, et al.
Cancer|June 5, 2020
MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancersJiajia Gu, Weilong Yao, Puyu Shi, et al.
Clinical and Diagnostic Laboratory Immunology|November 1, 2001
Correlation of CD4(+) T-Cell counts estimated by an immunocapture technique (Capcellia) with viral loads in human immunodeficiency virus-seropositive individualsR Kannangai, S Ramalingam, M V Jesudason, et al.
Cell and Tissue Banking|August 29, 2019
Verifying measurements of residual calcium content in demineralised cortical boneA F Ariffin, N Yusof, S Mohd, et al.
International Journal of Cancer|July 22, 2009
Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cellsTaofeek K Owonikoko, Suresh S Ramalingam, Beatriz Kanterewicz, et al.
Oncoscience|October 27, 2015
Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cellsPhilip J Webber, Chanhee Park, Min Qui, et al.
Cancer|January 31, 2020
Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)Hongjing Zang, Guoqing Qian, Dan Zong, et al.
Molecular Oncology|February 1, 2020
Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiolHongjing Zang, Guoqing Qian, Jack Arbiser, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|August 15, 2000
Peripheral CD4+/CD8+ T-lymphocyte counts estimated by an immunocapture method in the normal healthy south Indian adults and HIV seropositive individualsR Kannangai, K J Prakash, S Ramalingam, et al.
Pageof 51

Showing results (161-170 of 502) with videos related to

Sort By:
Pageof 51
Current Oncology (Toronto, Ont.)|December 31, 2015
Analysis of liver-directed therapies in U.S. cancer patientsO B Alese, S Kim, Z Chen, et al.
Nature Reviews. Clinical Oncology|November 29, 2024
The changing treatment landscape of EGFR-mutant non-small-cell lung cancerFei Zhou, Haoyue Guo, Yang Xia, et al.
Cancer|June 5, 2020
MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancersJiajia Gu, Weilong Yao, Puyu Shi, et al.
Clinical and Diagnostic Laboratory Immunology|November 1, 2001
Correlation of CD4(+) T-Cell counts estimated by an immunocapture technique (Capcellia) with viral loads in human immunodeficiency virus-seropositive individualsR Kannangai, S Ramalingam, M V Jesudason, et al.
Cell and Tissue Banking|August 29, 2019
Verifying measurements of residual calcium content in demineralised cortical boneA F Ariffin, N Yusof, S Mohd, et al.
International Journal of Cancer|July 22, 2009
Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cellsTaofeek K Owonikoko, Suresh S Ramalingam, Beatriz Kanterewicz, et al.
Oncoscience|October 27, 2015
Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cellsPhilip J Webber, Chanhee Park, Min Qui, et al.
Cancer|January 31, 2020
Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)Hongjing Zang, Guoqing Qian, Dan Zong, et al.
Molecular Oncology|February 1, 2020
Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiolHongjing Zang, Guoqing Qian, Jack Arbiser, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|August 15, 2000
Peripheral CD4+/CD8+ T-lymphocyte counts estimated by an immunocapture method in the normal healthy south Indian adults and HIV seropositive individualsR Kannangai, K J Prakash, S Ramalingam, et al.
Pageof 51